MDPI and ACS Style
Kadono, Y.; Konaka, H.; Nohara, T.; Izumi, K.; Anai, S.; Fujimoto, K.; Koguchi, T.; Ishibashi, K.; Kawai, N.; Nakane, K.;
et al. Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers 2023, 15, 2745.
https://doi.org/10.3390/cancers15102745
AMA Style
Kadono Y, Konaka H, Nohara T, Izumi K, Anai S, Fujimoto K, Koguchi T, Ishibashi K, Kawai N, Nakane K,
et al. Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers. 2023; 15(10):2745.
https://doi.org/10.3390/cancers15102745
Chicago/Turabian Style
Kadono, Yoshifumi, Hiroyuki Konaka, Takahiro Nohara, Kouji Izumi, Satoshi Anai, Kiyohide Fujimoto, Tomoyuki Koguchi, Kei Ishibashi, Noriyasu Kawai, Keita Nakane,
and et al. 2023. "Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study" Cancers 15, no. 10: 2745.
https://doi.org/10.3390/cancers15102745